Black Diamond Therapeutics Inks Licensing Pact With French Pharma Firm Servier For Its Early-Stage Cancer Drug Worth Over $700 Million

Servier Laboratories and Black Diamond Therapeutics Inc. BDTX on Wednesday announced a strategic worldwide licensing agreement for BDTX-4933 for solid tumors.

Servier is a pharmaceutical company based in France governed by a non-profit foundation.

Under the agreement, Servier will develop and commercialize BDTX-4933, a small molecule designed by Black Diamond Therapeutics for RAF/RAS-mutant solid tumors.

Under the terms of the deal, Servier will lead the development activities and the worldwide commercialization of BDTX-4933 across multiple indications, including non-small cell lung cancer, with potential applications in other solid tumors.

Also Read: Black Diamond Therapeutics’ Lead Drug Candidate Shows Initial Anti-Tumor Activity In Certain Type Of Lung Cancer Resistant To AstraZeneca’s Drug

Black Diamond Therapeutics will receive an upfront payment of $70 million and be eligible to receive up to $710 million in development and commercial sales milestone payments, along with tiered royalties based on global net sales.

Currently, in Phase 1 development, BDTX-4933 is designed to target RAS and RAF alterations in solid tumors.

The dose escalation and expansion cohort first-in-human study aims to evaluate the safety and tolerability, the preliminary recommended Phase 2 dose, and the anti-tumor activity of BDTX-4933 in adults with recurrent advanced/metastatic cancers harboring BRAF, CRAF, or NRAS mutations.

Black Diamond Therapeutics is developing BDTX-1535 for newly diagnosed patients with non-classical epidermal growth factor receptor mutant non-small cell lung cancer. Initial Phase 2 data are expected in the second quarter of this year, and Updated Phase 2 clinical data are expected in the second half of 2025.

Black Diamond ended 2024 with approximately $98.6 million in cash, cash equivalents, and investments, which is anticipated to provide a cash runway into the fourth quarter of 2026.

Price Action: BDTX stock is up 35.7% at $2.28 during at the last check Wednesday.

Read Next:

• Tencent Q4 Earnings Soar: 30% Surge In Net Income, Strong Performance From Games And AI

Image via Shutterstock